Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.
Cytometry B Clin Cytom
; 106(3): 162-170, 2024 05.
Article
in En
| MEDLINE
| ID: mdl-38418432
ABSTRACT
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there are limited options for reliable BCMA CAR T detection assays for physicians and researchers looking to explore it as a biomarker for clinical outcome. Given the known association of CAR T cell expansion kinetics with toxicity and response, being able to quantify BCMA CAR T cells routinely and accurately in the blood of patients can serve as a valuable asset. Here, we optimized an accurate and sensitive flow cytometry test using a PE-conjugated soluble BCMA protein, with a lower limit of quantitation of 0.19% of CD3+ T cells, suitable for use as a routine assay for monitoring the frequency of BCMA CAR T cells in the blood of patients receiving either ciltacabtagene autoleucel or idecabtagene vicleucel.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
B-Cell Maturation Antigen
/
Flow Cytometry
/
Receptors, Chimeric Antigen
/
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Cytometry B Clin Cytom
/
Cytometry, Part B Clin. cytom
/
Cytometry. Part B, Clinical cytometry
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos